Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515182 | 1.00 | PPARG (0.50) | PPARGPPARABLMSRRMMP7 | |
| SCHEMBL6903818 | 0.88 | PPARG (0.52) | PPARGPPARABLMSRR | |
| SCHEMBL8142297 | 0.86 | MEN1 (0.43) | PPARGPPARABLM | |
| SCHEMBL7344531 | 0.86 | BLM (0.41) | PPARGPPARABLM | |
| SCHEMBL5012826 | 0.86 | BLM (0.41) | PPARGPPARABLM | |
| SCHEMBL7728941 | 0.86 | MEN1 (0.43) | PPARGPPARABLM | |
| SCHEMBL7375987 | 0.86 | BLM (0.41) | PPARGPPARABLM | |
| SCHEMBL7726567 | 0.86 | MEN1 (0.43) | PPARGPPARABLM | |
| SCHEMBL1858577 | 0.85 | SMN1; SMN2 (0.46) | PPARGPPARABLM | |
| SCHEMBL9773201 | 0.85 | SMN1; SMN2 (0.46) | PPARGPPARABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543225-B1 | METHOD FOR PREPARING LISINOPRIL INTERMEDIATE | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-10633329-B2 | Method for preparing lisinopril intermediate | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-28 | — | — | US | disclosed |
| EP-3543225-A1 | METHOD FOR PREPARING LISINOPRIL INTERMEDIATE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2019-09-25 | — | — | EP | disclosed |
| CN-1585744-A | Process for the preparation of benazepril | RANBAXY LAB LTD (IN) | 2005-02-23 | — | — | CN | disclosed |
| US-6281352-B1 | ANTIINFLAMMATORY AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-08-28 | — | — | US | disclosed |
| EP-0863885-A2 | NOVEL MACROCYCLIC COMPOUNDS AS METALLOPROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997018207-A2 | NOVEL MACROCYCLIC COMPOUNDS AS METALLOPROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| US-5225408-A | Biphenyl oxadiazinone angiotensin II inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-07-06 | — | — | US | disclosed |
| US-4857520-A | Fused azepinone and azocinone derivatives, processes for their preparation, agents containing them and their use, and intermediates in their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633329-B2 | Method for preparing lisinopril intermediate | PKLR, PHYKPL, ACE | PPARG 2383/4885PPARA 1319/4885BLM 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.